A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

1.7K views

⸱

DOI:

10.3791/67260

⸱

May 9th, 2025

 ,  ,  ,  ,  ,  , 

In This Article

Summary

IDH1-mutant diffuse low-grade gliomas are rare tumors that are difficult to culture. We introduce a simple, non-enzymatic explant method that preserves IDH1-mutant protein expression and sustains cultures for months. Importantly, this technique works with cryopreserved tumors, offering a valuable resource for glioma research.

Abstract

Diffuse gliomas, the most prevalent primary brain tumors, are categorized into low and high grades based on histopathological criteria and genetic mutations. Diffuse low-grade gliomas constitute a subset, predominantly afflicting young adults and predisposing to high-grade gliomas. There are two main types of diffuse low-grade gliomas: astrocytomas and oligodendrogliomas, each defined by distinct genetic and histological features. These tumors characteristically exhibit a mutated variant of the metabolic enzyme IDH1, disrupting cellular differentiation. They are heterogeneous, comprising both proliferative stem cells and more differentiated, quiescent glial cells.

Patient-specific, in vitro tumor models hold significant potential for unraveling oncogenic mechanisms and tailoring drug selection for personalized therapy. However, the absence of reliable in vitro models specifically for IDH1-mutant low-grade gliomas has hindered fundamental and translational research. Here, we present a simple method for culturing IDH1-mutant tumors as explants in defined media without needing enzymatic dissociation. These explants can be sustained for extended periods, maintaining IDH1-mutant protein expression as well as markers for oligodendrocyte progenitor cells such as ASCL1 (MASH1), OLIG1, and OLIG2 and for astrocytes (GFAP, SOX9). They can also be established from frozen tumors in DMSO. These cultures can serve as a valuable platform for drug screening, videomicroscopy, and gene studies, thus facilitating advancements in understanding and treating these challenging tumors. They also offer the potential to derive IDH1-mutant cell lines.

Introduction

Diffuse gliomas are the most frequent primary brain tumors. These tumors are currently incurable despite very intense treatment (surgery, radio, and chemotherapy)1. Increasing evidence supports the hypothesis that gliomagenesis originates from adult stem or glial progenitor cells resident in the brain2. Although glioblastomas represent the most aggressive type, diffuse low-grade gliomas (DLGG, grade 2 tumors) are also prevalent (15% of diffuse gliomas)1,3. DLGGs grow slowly and migrate along white matter tracts, a hallmark of this 'diffuse' neoplasm<....

Access restricted. Please log in or start a trial to view this content.

Protocol

The tumor fragments utilized in this protocol were obtained from a well-characterized and ethically approved collection, with patient consent. This research was conducted under the project titled Gliomacult: Characterization and Primary Cultures of Low-Grade Gliomas (Project No. RECH/P722/1-5) and was approved by the tumor biobank's scientific council on August 28, 2023.

1. Preparation of culture plates

NOTE: Perform these steps under a sterile tissue culture laminar flow hood.

  1. At least 1 h before culture, prepare poly-D-lysine (PDL) and laminin-coated 24 well plates.
      ....

Access restricted. Please log in or start a trial to view this content.

Results

After a few days, some tumor fragments will adhere to the well surfaces, initiating the outgrowth of cells from the explants. The time between the initial plating and the appearance of tumoral growing cells is different from sample to sample. The initial cultures often contain substantial cellular debris, making it difficult to assess the presence of viable cells. Consequently, the culture should be maintained for a minimum of 4 weeks. Once the cells start to grow, elongated cells with a bipolar or multipolar appearance .......

Access restricted. Please log in or start a trial to view this content.

Discussion

Developing in vitro and preclinical models for IDH1-mutant low-grade gliomas is particularly challenging due to the slow growth of these tumors and the complexity of replicating the extensive genomic and epigenomic alterations caused by the IDH mutation. Moreover, these infiltrative tumor cells actively interact with surrounding cells, including immune, endothelial, glial, and neuronal cells, potentially relying on them for survival. This complex interplay is difficult to replicate in a laboratory setting.

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to declare.

Acknowledgements

The tumor fragments used here are part of the NEUROLOGY collection of fresh tissue samples maintained by the Biological Resource Center at Montpellier University Hospital (CRB@chu-montpellier.fr). This research was conducted under the project titled "Gliomacult: Characterization and Primary Cultures of Low-Grade Gliomas," led by Prof. J. P. Hugnot (Project No. RECH/P722/1-5). This work was supported by La ligue contre le cancer, ARC (Association for Cancer Research), ARTC, ARTC SUD, Les Etoiles dans la mer, EMBALL'ISO, Région Occitanie, INCA. K.A.C is supported by the National Council of Humanities Science and Technology (CONAHCYT), Mexico, and the As....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Anti-ASCL1BD Pharmingen™556604Dilution 1:500
Anti-ATRXSigma-AldrichHPA001906Dilution 1:100
Anti-CD68AgilentM081401-2Dilution 1:500
Anti-GFAPAves LabsAB_2313547Dilution 1:500
Anti-IBA1Fujifilm Wako Antibodies019-19741Dilituion 1:1000
Anti-IDH1 (R132H) mouse Monoclonal AntibodyDianovaDIA-H09
Anti-Ki67BD Pharmingen™556003Dilituion 1:1000
Anti-OLIG1R&D Systems®AF2417Dulituion 1:300
Anti-OLIG2Sigma-AldrichMABN50Dilution 1:250
Anti-SOX9Abcam®EPR14335-78Dilution 1:100
B-27 Supplement (50x), minus vitamin AThermo Fisher Scientific12587010
Bovine Serum Albumin (BSA)CiteAbA-421-100
Ciprofloxacin HClSigma-AldrichPHR1044-1G
CoolCellCorning®432000Cell Freezing Container, for 12 x 1 mL or 2 mL Cryogenic Vials
Cover slip Ø, 13 mmKarl Hecht™ Assistent™328017
Dimethyl Sulfoxide (DMSO)Sigma-AldrichD8418
DMEM/F-12, no glutamineThermo Fisher Scientific21331020
DNAse ISigma-Aldrich10104159001
Dulbecco′s Phosphate Buffered Saline (PBS) 1xSigma-AldrichD8537
Falcon 100 mm TC-treated Cell Culture DishCorning®353003
Falcon 24-well Clear Flat BottomCorning®353047TC-treated Multiwell Cell Culture Plate, with Lid, Sterile 
FunginInvivoGenant-fn-1
GentamicinThermo Fisher Scientific15750-037
HeparinSigma-AldrichH3149-100KU
HEPESSigma-AldrichH-3375
Human EGFPeproTechAF-100-15-1MG
Human FGF-basicPeproTech100-18B-1MG
LamininSigma-AldrichL2020
L-GlutamineThermo Fisher Scientific25030-024
N-2 Supplement (100x )Thermo Fisher Scientific17502-048
PDLSigma-AldrichP7886
Serum acrodisc 37 mm syringe filter with GF/0.2 µm SuporPALL Corporation4525
Trypsin InhibitorThermo Fisher Scientific17075-029
Trypsin-EDTA (0.05%), phenol redThermo Fisher Scientific25300054
Zeiss Z1 Apotome 3 microscopeZeissstraight widefield epifluorescence microscope

References

  1. Dasgupta, P., Balasubramanyian, V., De Groot, J. F., Majd, N. K. Preclinical models of low-grade gliomas. Cancers (Basel). 15 (3), 596(2023).
  2. Tirosh, I., et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 539 (....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

IDH1 Mutant GliomasTumor Explant ProtocolOligodendrocyte Progenitor CellsAstrocyte MarkersTumor MicroenvironmentCryopreservation Protocol3D Tumor ModelsPersonalized Drug Screening